센세이 바이오테라퓨틱스SNSE 주가

Cantor Fitzgerald Initiates Coverage On Sensei Biotherapeutics with Overweight Rating

Cantor Fitzgerald analyst Li Watsek initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight rating.

♻️ 재탕LUCID CAPITAL MARKETS Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $50

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces Price Target of $50.

Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $55

Citigroup analyst Samantha Semenkow initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces Price Target of $55.

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕[DEFA14A] DEFA14A — DEFA14A

♻️ 재탕[8-K] 중대 사건 — 8-K

[DEFA14A] DEFA14A — DEFA14A

12 Health Care Stocks Moving In Friday's After-Market Session

Sensei Biotherapeutics Q1 EPS $(131.45) Misses $(0.62) Estimate

Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(131.45) per share which missed the analyst consensus estimate of $(0.62) by 21101.61 percent. This is a 2334.26 percent decrease over losses of $(5.40)

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancerTopline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026...